<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Acute medical and surgical management. In: Clinical guidelines for stroke management 2010.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Acute medical and surgical management. In: Clinical guidelines for stroke management 2010. Melbourne (Australia): National Stroke Foundation; 2010 Sep. p. 58-67.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Acute medical and surgical management. In: National Stroke Foundation. Clinical guidelines for acute stroke management. Melbourne (Australia): National Stroke Foundation; 2007 Oct. p. 22-9.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Cerebral artery occlusion, unspecified with cerebral infarction  (434.91); Cerebral artery occlusion, unspecified without mention of cerebral infarction  (434.90); Cerebral edema  (348.5); Hyperventilation  (786.01); Neurologic examination  (89.13); Unspecified intracranial hemorrhage  (432.9); Unspecified transient cerebral ischemia  (435.9)"/><FieldValue Value="MSH: Adrenal Cortex Hormones ; Analgesics, Non-Narcotic ; Anticoagulants ; Anticonvulsants ; Antihypertensive Agents ; Antipyretics ; Aspirin ; Brain Ischemia ; Complementary Therapies ; Craniotomy ; Decompression, Surgical ; Factor VIIa ; Glasgow Coma Scale ; Hematoma ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hyperventilation ; Hypoglycemic Agents ; Infarction, Middle Cerebral Artery ; Intracranial Hemorrhages ; Ischemic Attack, Transient ; Monitoring, Physiologic ; Neurologic Examination ; Neuroprotective Agents ; Neurosurgical Procedures ; Oxygen Inhalation Therapy ; Patient Care Team ; Registries ; Stereotaxic Techniques ; Stroke ; Thrombolytic Therapy ; Tissue Plasminogen Activator ; Vascular Surgical Procedures ; Vital Signs ; Vitamin K "/><FieldValue Value="MTH: Adrenal Cortex Hormones ; alteplase ; Anticoagulants ; Anticonvulsants ; Antihypertensive Agents ; Antipyretics ; Aspirin ; Brain hemorrhage ; Brain Ischemia ; Cerebral Edema ; Cerebral hemisphere hemorrhage ; Cerebrovascular accident ; Complementary therapies ; Factor VIIa ; Fluid Management ; Glasgow coma scale ; Hematoma ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hyperventilation ; Ischemic stroke ; Neurologic Examination ; Neurosurgical Procedures ; Oxygen Therapy Care ; Patient Monitoring ; prothrombin complex concentrates ; Registries ; Thrombolysis, function ; Transient Cerebral Ischemia ; Transient Ischemic Attack ; Vascular Surgical Procedures ; Vital signs ; Vitamin K "/><FieldValue Value="PDQ: acetylsalicyclic acid ; cerebral edema ; cerebral edema management ; recombinant tissue plasminogen activator ; thrombolytic therapy "/><FieldValue Value="SNOMEDCT_US: Alteplase  (108997009); Alteplase  (27638005); Alteplase  (37411004); Alteplase  (387152000); Anticoagulant  (372862008); Anticoagulant  (81839001); Anticonvulsant  (255632006); Anticonvulsant  (63094006); Antipyretic  (76644002); Aspirin  (387458008); Aspirin  (7947003); Cerebral artery occlusion  (20059004); Cerebral edema  (2032001); Cerebral edema control  (386232002); Cerebral hemisphere hemorrhage  (73020009); Cerebrovascular accident  (230690007); Complementary therapy  (225423004); Corticoid preparation  (21568003); Corticoid preparation  (79440004); Craniectomy  (36910002); Craniotomy  (25353009); Evacuation of hematoma from cerebellum  (171474001); Factor IX fraction products  (319905006); Factor VIIa products  (319918003); Factor VIIa products  (73801006); Fluid balance regulation  (276026009); Glasgow coma scale  (386554004); Hematoma  (35566002); Hematoma  (385494008); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Hyperventilation  (68978004); Hyperventilation therapy for traumatic brain injury  (438603002); Hypoglycemic agent  (312064005); Hypoglycemic agent  (373299009); Hypotensive agent  (1182007); Hypotensive agent  (372586001); Intracranial hemorrhage  (1386000); Ischemic encephalopathy  (389100007); Ischemic stroke  (422504002); Massive supratentorial cerebral hemorrhage  (230709005); Monitoring of patient  (182777000); Motor dysfunction  (264552009); Motor dysfunction  (52559000); Neurological assessment  (225398001); Neurological assessment  (84728005); Non-opioid analgesic  (322208004); Non-opioid analgesic  (373216001); Operation on nervous system  (16545005); Oxygen therapy  (57485005); Physiologic monitoring system  (5159002); Respiratory pattern  (278907009); Superficial bruising  (270911002); Surgical decompression - action  (410756002); Surgical decompression - action  (410803008); Thrombolysis  (51308000); Thrombolysis of artery  (233335005); Thrombolytic therapy  (426347000); Transient cerebral ischemia  (266257000); Vascular surgery procedure  (30904006); Vital signs  (46680005); Vitamin K  (65183007); Vitamin K  (74226000)"/><FieldValue Value="UMD: Monitoring Systems, Physiologic  (12-636); Procedure Kit/Trays, Oxygen Administration  (12-855); Workstations, Stereotactic Surgery  (21-966)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Transient ischaemic attack (TIA) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: These guidelines do not cover:&lt;/p&gt;&#xD;&#xA;&lt;ul class=&quot;contentListFont&quot;&gt;&#xD;&#xA;    &lt;li&gt;Subarachnoid haemorrhage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stroke in infants, children and youth (i.e. &amp;lt;18 years old), or &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Primary prevention of stroke (refer to Guidelines for the assessment of absolute cardiovascular disease risk 2009.) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Critical Care" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Neurological Surgery" /><FieldValue Value="Neurology" /><FieldValue Value="Preventive Medicine" /><FieldValue Value="Pulmonary Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Emergency Medical Technicians/Paramedics" /><FieldValue Value="Health Plans" /><FieldValue Value="Hospitals" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide evidence-based recommendations related to recovery from stroke and transient ischaemic attack (TIA) to assist decision-making based on the best evidence available at the time of development&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults (18 years or older) with stroke or transient ischemic attack (TIA) symptoms&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Thrombolysis&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Intravenous recombinant tissue plasminogen activator (rt-PA) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Intra-arterial (IA) thrombolysis &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antithrombotic therapy (aspirin) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acute phase blood pressure lowering therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring for neurological deterioration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgery (decompressive hemicraniectomy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of cerebral oedema (osmotherapy, hyperventilation) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intracerebral hemorrhage management&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Reverse anticoagulation (vitamin K, prothrombin complex) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Surgery for supratentorial haemorrhage &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Surgical evacuation &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Physiologic monitoring (neurological status [e.g., Glasgow coma scale], vital signs, respiratory pattern) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oxygen therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glycaemic control &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Neuroprotector therapy (as part of randomised controlled trial only) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Continuation of statin therapy for patients receiving statins prior to admission &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antipyretic therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Seizure management &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Corticosteroids and complementary alternative therapies were considered, but not recommended.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Thrombolysis rates &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Post-stroke seizures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rate of perioperative stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Morbidity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Death and dependency &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Functional outcome &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Finding Relevant Studies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Systematic identification of relevant studies was conducted between May and August 2009. An external consultant undertook all the electronic database searches. EMBASE, Medline and Cochrane databases were used for all questions. CINAHL and PsycINFO databases were searched where relevant (e.g., questions relating to rehabilitation, discharge planning or long-term recovery). The PEDro database was used by the National Stroke Foundation (NSF) project team to check studies related to physical therapy. A second updated search of the literature up to February 19, 2010 using Medline and EMBASE databases was conducted. Updated Cochrane reviews were also searched and included.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Where the questions were the same as those used in the previous acute management guidelines (2007), the literature was searched from the beginning of 2007. Where the questions were the same as those used in the previous rehabilitation guidelines (2005), the literature was searched from the beginning of 2005. For topics not previously addressed, searches were carried out from 1966 onwards.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Searching of EMBASE, Medline and Cochrane libraries was conducted in four broad steps:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Terms for the patient group were abridged from the Cochrane Collaboration's Stroke Group. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A second search term specific to the particular question (i.e., specific terms relevant to an intervention or assessment) was added. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Relevant evidence filters (Cochrane sensitive filter or Medline diagnostic filter) were applied. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the search was for an update to an authoritative meta-analysis (NSF or other), it was limited to the years after the relevant document was published. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;Search strategies are available from the NSF. Table A2.1 in the original guideline document outlines the number of articles found for each of the nine broad topic areas.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 39,930 potential articles were identified up until August 2009 and an additional 7337 at February 2010. Reference lists of identified articles and other guidelines were then used to identify further studies. Existing international guidelines identified and used included those published by the Scottish Intercollegiate Guidelines Network (SIGN), the National Institute for Health and Clinical Excellence UK, the Royal College of Physicians (London, UK), the Canadian Stroke Network and the Heart and Stroke Foundation of Canada, the American Heart/Stroke Association and the European Stroke Organisation. Correspondence with SIGN identified overlapping topics that had recently been systematically searched by SIGN and hence this information was kindly provided and used for several rehabilitation-related topics. A number of key journals were also searched by hand from October 2009 to March 2010: &lt;em&gt;Stroke, Cerebrovascular Disease, Lancet (&lt;/em&gt;and &lt;em&gt;Lancet Neurology),&lt;/em&gt; and &lt;em&gt;Archives of Physical Medicine and Rehabilitation&lt;/em&gt;. Further, an internet search was undertaken (using the 'Google' search engine). Finally, where possible, experts in the field were contacted to review the identified studies and suggest other new studies not yet identified.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One reviewer initially scanned the titles and available abstracts of all studies identified by the searches and excluded any clearly irrelevant studies. Based on the titles and abstracts of the remaining studies, two reviewers assessed and selected potentially eligible studies using the following inclusion criteria:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Type of study. Relevant systematic reviews were first identified. Where no systematic review was found, randomized controlled trials (RCTs) were searched. If there was a sparsity of Level I or Level II evidence, the search was expanded to consider lower levels of evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Type of participant. Initially only studies which included adults (&amp;gt;18 years) with stroke or transient ischaemic attack (TIA) were included. Studies in other related populations (e.g., general elderly population or those with traumatic brain injury) were then included if the particular intervention was deemed to be transferable to those with stroke. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Language. Only studies published in English were used. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Disagreements on inclusion of particular studies were resolved by consensus. If necessary a relevant member of the expert working group (EWG) provided a third and final vote.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In addition to the initial searches, economic literature was searched via the Australian Medical Index, Econlit, EMBASE, Medline, Health Technology Assessment, and National Health Service (NHS) Economic Evaluation Databases. Searches were carried out from the beginning of 2005 to identify papers published after the rehabilitation guidelines (2005). A total of 1033 references were retrieved after de-duplication (Table A2.2 in the original guideline document). One person initially reviewed all references and selected 44 potentially relevant articles. These abstracts were scrutinised by two people and 35 appropriate papers were retrieved and reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;35 appropriate papers were retrieved.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Designation of Levels of Evidence According to Type of Research Question&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Designation of Levels of Evidence According to Type of Research Question&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Intervention&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Diagnosis&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Prognosis&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Aetiology&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Screening&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A systematic review of Level II studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A systematic review of Level II studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A systematic review of Level II studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A systematic review of Level II studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A systematic review of Level II studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;II&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A randomised controlled trial&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A study of test accuracy with: an independent, blinded comparison with a valid reference standard, among consecutive patients with a defined clinical presentation&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A prospective cohort study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A prospective cohort study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A randomised controlled trial&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III-1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A pseudo-randomised controlled trial (i.e., alternate allocation or some other method)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A study of test accuracy with: an independent, blinded comparison with a valid reference standard, among consecutive patients with a defined clinical presentation&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;All or none&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;All or none&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A pseudo-randomised controlled trial (i.e., alternate allocation or some other method)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III-2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A comparative study with concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Non-randomised experimental trial &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cohort study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case-control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series without a parallel control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A comparison with a reference standard that does not meet the criteria required for Level II and Level III-1 evidence&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Analysis of prognostic factors amongst untreated control patients in a randomised controlled trial&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A retrospective cohort study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A comparative study with concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Nonrandomised, experimental trial &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cohort study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case-control study &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III-3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A comparative study without concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Historical control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Two or more single arm studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series without a parallel control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Diagnostic case-control study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A retrospective cohort study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A case-control study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A comparative study without concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Historical control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Two or more single arm studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IV&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series with either post-test or pre-test/post-test outcomes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Study of diagnostic yield (no reference standard)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series or cohort study of patients at different stages of disease&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A cross-sectional study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Appraising&amp;nbsp;the Selected Studies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A standardised appraisal process was used based on forms adapted from the Guidelines International Network and Scottish Intercollegiate Guideline Network (SIGN). Where available, appraisals already undertaken by SIGN for the rehabilitation section were used to avoid duplication. The standardised appraisal form assesses the level of evidence (design and issues of quality), size of effect, relevance, applicability (benefits/harms) and generalisability of studies. Examples of completed checklists can be obtained from the National Stroke Foundation (NSF). Evidence for diagnostic and prognostic studies was also appraised using the SIGN methodology.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Summarising and Synthesising the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Details of relevant studies were summarised in evidence tables which form a supplement to this document and can be downloaded from the NSF website (&lt;a href=&quot;http://www.strokefoundation.com.au/&quot; title=&quot;NSF Australia Web site&quot;&gt;www.strokefoundation.com.au&lt;/a&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To assist in the formulation of recommendations for each question, the National Health and Medical Research Council (NMHRC) Grades process (2008&amp;ndash;2010) was applied. No pooling of data or meta-analysis was undertaken during the evidence synthesis process.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Informal Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines were developed according to standards outlined by the National Health and Medical Research Council (NHMRC).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Question Formulation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Clinical questions used for previous guidelines were reviewed and duplication removed. A draft set of questions was developed by the National Stroke Foundation (NSF) project team and circulated to the expert working group (EWG). The EWG agreed on one hundred and thirty-four (134) specific clinical questions addressing interventions relevant to stroke care. The questions generally queried the effects of a specific intervention and were developed in three parts: the intervention, the outcomes and the population, for example, 'What is the effect of anticonvulsant therapy on reducing seizures in people with post-stroke seizures?' In this example, anticonvulsant therapy is the intervention, reduction of post-stroke seizures is the outcome, and the population is people with post-stroke seizures. The list of questions is available from the NSF.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Summarising and Synthesising the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For each question, the NSF project team developed a draft recommendation based on the NHMRC matrix (Table A2.3 in the original guideline document). These recommendations were subsequently discussed and agreed on by the EWG. Final decisions were made by informal group processes after open discussion facilitated by the co-chairs. The recommended grading matrix was used to guide the strength or grading of the recommendation (Table A2.4 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Following agreement on recommendations, the NSF project team drafted the body of the guidelines which included a brief discussion of the evidence and other relevant factors such as the current gaps in practice as outlined in the most recent National Stroke Audits or considerations regarding implementation. Early drafts were circulated for comment by the EWG and amended before release for public consultation.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grading of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: Grades of Recommendations&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Description&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice in most situations&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence provides some support for recommendation(s) but care should be taken in its application&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence is weak and recommendation must be applied with caution&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Good Practice Point (GPP)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommended best practice based on clinical experience and expert opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Cost and Socioeconomic Implications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The lifetime costs of first-ever stroke have been recently estimated to be more than $2 billion in Australia (net present value 2004). Therefore, providing cost-effective stroke care (prevention management and treatment) is important to avoid unnecessary costs to society. This section presents an updated review of the cost and socioeconomic implications of providing evidence-based stroke care given the recommendations within these guidelines. The expert working group (EWG) (including a search specialist) conducted a separate systematic review for this section. A broad search strategy was used to search the following databases: Econlit, EMBASE, Medline, Health Technology Assessment, National Health Service (NHS) Evaluations and Australasian Medical Index (the search strategy used is available from the National Stroke Foundation). The search yielded 1033 abstracts which were reviewed by one member of the project team. Forty-four potential studies were selected for further consideration.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Staff at the National Stroke Research Institute, a subsidiary of Florey Neuroscience Institutes, scrutinised the 44 abstracts published between 2005 and 2009 for omissions and appropriate papers were retrieved and reviewed. As the breadth of topics was wide and the methods used quite disparate, a narrative review was deemed the most appropriate way to summarise the cost and socioeconomic evidence. There was also a preference to report evidence from studies undertaken in Australia. Therefore, if similar work had been undertaken elsewhere, this information was not included in the summary unless the results were relevant to the findings in Australia. This is because it is often difficult to extrapolate from international studies to the Australian context given differences in health services provision and funding, target populations and interventions such as drug dosages.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The discussion related to the cost-effectiveness evidence is presented to follow the structure of the guidelines document. It should be noted that these guidelines include several consensus recommendations or recommendations based on levels of evidence below Level II for a number of 'micro' clinical practice issues (e.g., physiological monitoring and oxygen therapy). As such, it is not possible to analyse the implications of these sorts of recommendations, as they in fact often form part of a larger package or program of care for which there is Level I evidence (for example, stroke units). Furthermore, there is limited cost-effectiveness evidence available for many acute stroke care interventions and often these types of studies have not been conducted. Therefore, evidence and discussion for the main (strongest) recommendations in these guidelines is provided. This review is also an extension of the summaries provided in the earlier versions of the stroke clinical guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Conclusions &lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There is good cost-effectiveness evidence for the most clinically effective stroke prevention and treatment strategies recommended in these guidelines. In particular, stroke unit care, thrombolysis, blood pressure lowering, warfarin for atrial fibrillation (AF), aspirin for stroke prevention and carotid endarterectomy were all determined to be worthwhile from an economic perspective. The findings for intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) administered within three hours of acute ischaemic stroke were consistently found to be cost-saving from a lifetime perspective. However, there is limited evidence for the cost-effectiveness of rt-PA used up to 4.5 hours and further research is needed. There is sufficient evidence for the cost-effectiveness of antithrombotic therapy with dipyridamole plus aspirin compared to aspirin alone in secondary stroke prevention. There is also sufficient evidence for blood pressure lowering with angiotensin-converting enzyme (ACE) inhibitors in all stroke and transient ischaemic attack (TIA) patients, as recommended by these guidelines. This review also allowed the developers to identify a range of areas where additional cost-effectiveness studies would complement health outcome data, including an assessment of home-based stroke rehabilitation, rapid assessment clinics for TIA, carer training, the use of botulinum toxin A for stroke patients with persistent moderate to severe spasticity and imaging modalities for selecting patients for intravenous thrombolysis. One major factor that may influence the economic implications of interventions found to be cost-effective is access and population coverage. In a recent modelling exercise in the Australian setting, it was found that more widely accessible, evidence-based stroke care could produce substantial economic and health-related benefits and would require only modest investment. The authors suggested that if there was improved access to effective acute care (stroke units and intravenous thrombolysis) and secondary prevention (BP lowering, warfarin for AF, aspirin in ischaemic stroke and carotid endarterectomy) and improved management of BP and AF as primary prevention in the Australian population, then about $1.06 billion could be recovered as potential cost-offsets with recovery of more than 85,000 DALYs. Therefore, clinical guidelines such as these which promote improved treatment and prevention of stroke are an important contribution to achieving such increased access and cost-effective use of health resources in this country.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Chapter 9 in the original guideline document for a full discussion of cost analysis.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Consultation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Public consultation about the draft document was undertaken over one month from February to March 2010. A specific feedback form was circulated via the Australian Stroke Coalition and members of the expert working group (EWG) and advisory group to relevant professional bodies, stroke clinical networks, consumers and consumer organisations. A public notice was published in The Australian newspaper (1 February 2010) in line with National Health and Medical Research Council (NHMRC) requirements. The draft document was also posted on the National Stroke Foundation website.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Over 460 individual comments covering a wide range of topics were received from 77 individuals, groups or organisations. Feedback received was initially considered by the NSF project team with minor amendments such as formatting or spelling reviewed and actioned. Other feedback was forwarded to relevant members of the EWG depending on topic areas and suggested responses developed. All comments and suggested responses were collated and circulated to the full EWG for consideration and discussion, with several topics being further discussed during subsequent teleconferences. Informal consensus processes were used to modify any recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A significant number of the comments received during consultation related to the structure of the document, the size of some of the chapters and the ambiguity of some the recommendations. As a result of the feedback, significant structural changes to the order of contents of the guidelines were made. Other minor rewording and reformatting was also carried out. The sequencing of the recommendations was also reviewed and modified where appropriate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Several topics received significantly more feedback than others and the EWG's responses are listed below:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Acute blood pressure therapy: recommendation specific to intracranial haemorrhage (ICH) added &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Behavioural management: further section added to expand this information &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cognitive communication deficits: further section added to expand this information &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Contracture: revision of preamble regarding prolonged stretches and relevant recommendation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Loss of sensation: revision of preamble and recommendations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Neurointervention: rewording of recommendation regarding mechanical retrieval devices &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Spasticity: revision of preamble &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Transient ischaemic attack (TIA) management: revision of both organisation and clinical management preambles and minor changes to recommendations &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Minor changes were also made to aphasia, cognition, incontinence, thrombolysis and dysphagia. For other topics, apart from a change in order and minor wording changes, none of the recommendations were significantly changed after feedback from consultation. Five questions, modified from key questions included in the Guidelines Implementability Tool, were also included in the consultation feedback form to provide general feedback. This feedback was used by the National Stroke Foundation (NSF) project team when reviewing and updating the draft document. Recommendations that were unclear or ambiguous were reworded. A medical editor also reviewed the guidelines to ensure that there was consistency in the language used and the presentation of the evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A letter of reply outlining the EWG's responses was sent to all individuals and organisations who provided feedback during the public consultation period. A list of individuals, groups or organisations who provided feedback during the consultation process can be obtained from the NSF.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The updated guideline document underwent one final round of peer review by international experts in the field of stroke and guideline development.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Feedback received was initially reviewed by the NSF project team and the EWG co-chairs and minor changes were made (slight wording changes to several recommendations). The final document was circulated to the EWG for sign-off and then submitted to the NHMRC for consideration of approval.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;These guidelines were approved by the Chief Executive Officer of the NHMRC on 3rd August 2010, under Section 14A of the National Health and Medical Research Council Act 1992. In approving these guidelines the NHMRC considers that they meet the NHMRC standard for clinical practice guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The grades of recommendations (A-D and good practice point [GPP]) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Thrombolysis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Intravenous recombinant tissue plasminogen activator (rt-PA) in acute ischaemic stroke should only be undertaken in patients satisfying specific inclusion and exclusion criteria. (&lt;strong&gt;Grade A&lt;/strong&gt; [Wardlaw et al., 2009])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Intravenous rt-PA should be given as early as possible in carefully selected patients with acute ischaemic stroke as the effect size of thrombolysis is time-dependent. Where possible, therapy should commence in the first few hours but may be used up to 4.5 hours after stroke onset. (&lt;strong&gt;Grade A&lt;/strong&gt; [Wardlaw et al., 2009; Lansberg et al., 2009])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Intravenous rt-PA should only be given under the authority of a physician trained and experienced in acute stroke management. (&lt;strong&gt;Grade B&lt;/strong&gt; [Wardlaw et al., 2009])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Thrombolysis should only be undertaken in a hospital setting with appropriate infrastructure, facilities and network support including:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Access to an multidisciplinary acute care team with expert knowledge of stroke management who are trained in delivery and monitoring of patients receiving thrombolytic therapy (&lt;strong&gt;GPP&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pathways and protocols available to guide medical, nursing and allied health acute phase management, in particular acute blood pressure management (&lt;strong&gt;Grade C&lt;/strong&gt; [Graham, 2003; Ahmed et al., 2009; Butcher et al., 2010]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immediate access to imaging facilities and staff trained to interpret images. (&lt;strong&gt;GPP&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;A minimum set of de-identified data from all patients treated with thrombolysis should be recorded in a central register to allow monitoring, review, comparison and benchmarking of key outcomes measures over time. (&lt;strong&gt;Grade C&lt;/strong&gt; [Wahlgren et al., 2007])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The commencement of aspirin for patients who have received thrombolysis should be delayed for 24 hours (usually after a follow-up scan has excluded significant bleeding). (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Neurointervention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Intra-arterial (IA) thrombolysis within six hours can be used in carefully selected patients. (&lt;strong&gt;Grade B&lt;/strong&gt; [Wardlaw et al., 2009])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Each large tertiary centre should consider establishing facilities and systems for IA thrombolysis. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There is insufficient evidence to recommend the use of mechanical clot removal in routine clinical practice. Consideration should be given to enrolling patients in a suitable clinical trial evaluating this intervention. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Antithrombotic Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Aspirin orally or via a nasogastric tube or suppository (for those with dysphagia) should be given as soon as possible after the onset of stroke symptoms (i.e., within 48 hours) if computed tomography/magnetic resonance imaging (CT/MRI) scans exclude haemorrhage. The first dose should be at least 150 to 300 mg. Dosage thereafter can be reduced (e.g., 100 mg daily). (&lt;strong&gt;Grade A&lt;/strong&gt; [Sandercock et al., 2008])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The routine use of early anticoagulation in unselected patients following ischaemic stroke/transient ischaemic attack (TIA) is NOT recommended. (&lt;strong&gt;Grade A&lt;/strong&gt; [Sandercock, Counsell, &amp;amp; Tseng, 2008])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Acute Phase Blood Pressure Lowering Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In ischaemic stroke, if blood pressure is more than 220/120 mmHg, antihypertensive therapy can be started or increased, but blood pressure should be cautiously reduced (e.g., by no more than 10&amp;ndash;20%) and the patient monitored for signs of neurological deterioration. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In acute primary intracerebral haemorrhage where severe hypertension is observed on several occasions within the first 24 to 48 hours of stroke onset, antihypertensive therapy (that could include intravenous treatment) can be used to maintain a blood pressure below 180 mmHg systolic (mean arterial pressure of 130 mmHg). (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Pre-existing antihypertensive therapy can be continued (orally or via nasogastric tube) provided there is no symptomatic hypotension or other reason to withhold treatment. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Surgery for Ischaemic Stroke and Management of Cerebral Oedema&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Selected patients (18&amp;ndash;60 years, where surgery can occur within 48 hours of symptom onset) and with large middle cerebral artery infarction should be urgently referred to a neurosurgeon for consideration of decompressive hemicraniectomy. (&lt;strong&gt;Grade A&lt;/strong&gt; [Vahedi et al., 2007])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Corticosteroids are NOT recommended for management of patients with brain oedema and raised intracranial pressure. (&lt;strong&gt;Grade A&lt;/strong&gt; [Qizilbash, Lewington, &amp;amp; Lopez-Arrieta, 2002])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Osmotherapy and hyperventilation can be trialled while a neurosurgical consultation is undertaken, or in patients whose condition is deteriorating due to raised intracranial pressure. (&lt;strong&gt;Grade C&lt;/strong&gt; [Righetti et al., 2004; Hofmeijer, van der Worp, &amp;amp; Kappelle, 2003]).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Intracerebral Haemorrhage Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The use of haemostatic drug treatment with recombinant activated factor VII (rFVIIa) is currently considered experimental and is NOT recommended for use outside a clinical trial. (&lt;strong&gt;Grade B&lt;/strong&gt; [You &amp;amp; Al-Shahi, 2006])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with intracerebral hemorrhage (ICH) who were receiving anticoagulation therapy prior to the stroke and who have elevated international normalised ratio (INR), therapy to reverse anticoagulation should be initiated rapidly (e.g., using a combination of prothrombin complex concentrate and vitamin K). (&lt;strong&gt;Grade D&lt;/strong&gt; [Aguilar et al., 2007; Steiner, Rosand, &amp;amp; Diringer, 2006])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with supratentorial ICH should be referred for neurosurgical review if they have hydrocephalus. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Surgery for supratentorial haemorrhage can be considered in carefully selected patients. If undertaken, surgery should be performed within 72 hours. The strongest evidence for benefit with surgery is for patients aged &amp;lt;85, a Glasgow Coma Score of 5&amp;ndash;15 having altered consciousness or severe neurological deficit and presenting within 24 hours. (&lt;strong&gt;Grade C&lt;/strong&gt; [Prasad, Mendelow, &amp;amp; Gregson, 2008])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Surgical evacuation may be undertaken for cerebellar hemisphere haematomas &amp;gt;3 cm diameter in selected patients. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Physiological Monitoring&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients should have their neurological status (e.g., Glasgow Coma Scale), vital signs (including pulse, blood pressure, temperature, oxygen saturation, and glucose levels) and respiratory pattern monitored and documented regularly during the acute phase, the frequency of such observations being determined by the patient's status. (&lt;strong&gt;Grade C&lt;/strong&gt; [Silva et al., 2005; Cavallini et al., 2003; Roquer et al., 2008; Sulter et al., 2003])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Oxygen Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients who are hypoxic (i.e., &amp;lt;95% oxygen saturation) should be given supplemental oxygen. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The routine use of supplemental oxygen is NOT recommended in acute stroke patients who are not hypoxic. (&lt;strong&gt;Grade C&lt;/strong&gt; [Ronning &amp;amp; Guldvog, 1999])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Glycaemic Control&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;On admission, all patients should have their blood glucose level monitored and appropriate glycaemic therapy instituted to ensure euglycaemia, especially if the patient is diabetic. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An early intensive approach to the maintenance of euglycaemia is currently NOT recommended. (&lt;strong&gt;Grade B&lt;/strong&gt; [Gray et al., 2007])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Neuroprotection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Putative neuroprotectors (including hypothermic cooling) should only be used in a randomised controlled trial. (&lt;strong&gt;Grade A&lt;/strong&gt; [Diener et al., 2008; Bath 2004; den Hertog et al., 2009; Doesborgh et al., 2004; Rose, Douglas, &amp;amp; Matyas, 2002])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with acute ischaemic stroke who were receiving statins prior to admission can continue statin treatment. (&lt;strong&gt;Grade B&lt;/strong&gt; [Blanco et al., 2007])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pyrexia Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Antipyretic therapy, comprising regular paracetamol and/or physical cooling measures, should be used routinely where fever occurs. (&lt;strong&gt;Grade C&lt;/strong&gt; [den Hertog et al., 2009; Mayer et al., 2004])&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Seizure Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Anti-convulsant medication should be used for people with recurrent seizures after stroke. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Complementary and Alternative Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The routine use of the following complementary and alternative therapies is NOT recommended:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Acupuncture (&lt;strong&gt;Grade B&lt;/strong&gt; [Zhang et al., 2005]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Traditional Chinese herbal medicines (&lt;strong&gt;Grade B&lt;/strong&gt; [Li et al., 2009; Cao et al., 2008; Tan, Liu, &amp;amp; Wu, 2008; Zeng et al., 2005; Wu, Liu, &amp;amp; Zhang, 2007; Chen et al., 2008; Zhuo et al., 2008; Yan &amp;amp; Hui-Chan, 2009]) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Health professionals should be aware of different forms of complementary and alternative therapies and be prepared to discuss these with stroke survivors and their families/carers. (&lt;strong&gt;GPP&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grading of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: Grades of Recommendations&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Description&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice in most situations&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence provides some support for recommendation(s) but care should be taken in its application&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence is weak and recommendation must be applied with caution&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Good Practice Point (GPP)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommended best practice based on clinical experience and expert opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC, Ansell JE, Mayer SA, Norrving B, Rosand J, Steiner T, Wijdicks EF, Yamaguchi T, Yasaka M. Treatment of warfarin-associated intracerebral hemorrhage: literature review and  expert opinion. Mayo Clin Proc. 2007 Jan;82(1):82-92. [86 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17285789&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D, SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register . Stroke. 2009 Jul;40(7):2442-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19461022&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bath PM. Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;(3):CD000211. [21 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15266427&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, Davalos A, Castillo J. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007 Aug 28;69(9):904-10. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17724294&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Butcher K, Christensen S, Parsons M, De Silva DA, Ebinger M, Levi C, Jeerakathil T, Campbell BC, Barber PA, Bladin C, Fink J, Tress B, Donnan GA, Davis SM, EPITHET Investigators. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke. 2010 Jan;41(1):72-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19926841&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cao W, Liu W, Wu T, Zhong D, Liu G. Dengzhanhua preparations for acute cerebral infarction. Cochrane Database Syst Rev. 2008;(4):CD005568. [45 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18843694&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cavallini A, Micieli G, Marcheselli S, Quaglini S. Role of monitoring in management of acute ischemic stroke patients. Stroke. 2003 Nov;34(11):2599-603. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14563969&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chen X, Zhou M, Li Q, Yang J, Zhang Y, Zhang D, Kong S, Zhou D, He L. Sanchi for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;(4):CD006305. [169 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18843711&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;den Hertog HM, van der Worp HB, van Gemert HM, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ, Dippel DW, PAIS Investigators. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol. 2009 May;8(5):434-40. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19297248&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, Hardemark HG, Rodichok L, SAINT I and II Investigators. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II  Trials. Stroke. 2008 Jun;39(6):1751-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18369171&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Doesborgh SJ, van de Sandt-Koenderman MW, Dippel DW, van Harskamp F, Koudstaal PJ, Visch-Brink EG. Effects of semantic treatment on verbal communication and linguistic processing in aphasia after stroke: a randomized controlled trial. Stroke. 2004 Jan;35(1):141-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14657447&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003 Dec;34(12):2847-50. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14605319&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gray CS, Hildreth AJ, Sandercock PA, O'Connell JE, Johnston DE, Cartlidge NE, Bamford JM, James OF, Alberti KG, GIST Trialists Collaboration. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007 May;6(5):397-406. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17434094&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hofmeijer J, van der Worp HB, Kappelle LJ. Treatment of space-occupying cerebral infarction. Crit Care Med. 2003 Feb;31(2):617-25. [169 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12576974&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009 Jul;40(7):2438-41. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19478213&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Li W, Liu M, Feng S, Wu B, Zhang S, Yang W, Liu GJ. Acanthopanax for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;(3):CD007032. [45 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19588417&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mayer SA, Kowalski RG, Presciutti M, Ostapkovich ND, McGann E, Fitzsimmons BF, Yavagal DR, Du YE, Naidech AM, Janjua NA, Claassen J, Kreiter KT, Parra A, Commichau C. Clinical trial of a novel surface cooling system for fever control in neurocritical care patients. Crit Care Med. 2004 Dec;32(12):2508-15. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15599159&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Prasad K, Mendelow AD, Gregson B. Surgery for primary supratentorial intracerebral haemorrhage. Cochrane Database Syst Rev. 2008;(4):CD000200. [37 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18843607&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Qizilbash N, Lewington SL, Lopez-Arrieta JM. Corticosteroids for acute ischaemic stroke. Cochrane Database Syst Rev. 2002;(2):CD000064. [29 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12076379&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Righetti E, Celani MG, Cantisani T, Sterzi R, Boysen G, Ricci S. Glycerol for acute stroke. Cochrane Database Syst Rev. 2004;(2):CD000096. [28 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15106142&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ronning OM, Guldvog B. Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. Stroke. 1999 Oct;30(10):2033-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512903&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Roquer J, Rodriguez-Campello A, Gomis M, Jimenez-Conde J, Cuadrado-Godia E, Vivanco R, Giralt E, Sepulveda M, Pont-Sunyer C, Cucurella G, Ois A. Acute stroke unit care and early neurological deterioration in ischemic stroke. J Neurol. 2008 Jul;255(7):1012-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18712428&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rose M, Douglas J, Matyas T. The comparative effectiveness of gesture and verval treatments for a specific phonologic naming impairment. Aphasiology. 2002;16(10/11):1001-30.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sandercock PA, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;(3):CD000029. [77 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18646056&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sandercock PA, Counsell C, Tseng MC. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;(3):CD000119. [45 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18646059&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Silva Y, Puigdemont M, Castellanos M, Serena J, Suner RM, Garcia MM, Davalos A. Semi-intensive monitoring in acute stroke and long-term outcome. Cerebrovasc Dis. 2005;19(1):23-30. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15528881&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006 Jan;37(1):256-62. [81 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16339459&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sulter G, Elting JW, Langedijk M, Maurits NM, De Keyser J. Admitting acute ischemic stroke patients to a stroke care monitoring unit versus  a conventional stroke unit: a randomized pilot study. Stroke. 2003 Jan;34(1):101-4. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12511758&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Tan Y, Liu M, Wu B. Puerarin for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;(1):CD004955. [28 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18254067&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, Algra A, Amelink GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W, DECIMAL, DESTINY, and HAMLET investigators. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007 Mar;6(3):215-22. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303527&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G, SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27;369(9558):275-82. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17258667&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;(4):CD000213. [148 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19821269&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wu B, Liu M, Zhang S. Dan shen agents for acute ischaemic stroke. In: Cochrane Database of Systematic Reviews [internet]. Issue 2. Hoboken (NJ): John Wiley &amp; Sons, Ltd.; 2007&amp;nbsp;[Art. No.: CD004295]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Yan T, Hui-Chan CW. Transcutaneous electrical stimulation on acupuncture points improves muscle function in subjects after acute stroke: a randomized controlled trial. J Rehabil Med. 2009 Apr;41(5):312-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19363561&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;You H, Al-Shahi R. Haemostatic drug therapies for acute primary intracerebral haemorrhage. In: Cochrane Database of Systematic Reviews [internet]. Issue 3. Hoboken (NJ): John Wiley &amp; Sons, Ltd.; 2006&amp;nbsp;[Art. No.: CD005951]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zeng X, Liu M, Yang Y, LiY, Asplund K. Ginko biloba for acute ischaemic stroke. In: Cochrane Database of Systematic Reviews [internet]. Issue 4. Hoboken (NJ): John Wiley &amp; Sons, Ltd.; 2005&amp;nbsp;[Art. No.: CD003691]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zhang SH, Liu M, Asplund K, Li L. Acupuncture for acute stroke. In: Cochrane Database of Systematic Reviews [internet]. Issue 2. Hoboken (NJ): John Wiley &amp; Sons, Ltd.; 2005&amp;nbsp;[Art. No.: CD003317]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zhuo Q, Yang X, Wu T, Liu G, Zhou L. Tongxinluo capsule for acute stroke. Cochrane Database Syst Rev. 2008;(4):CD004584. [55 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18843664&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see &quot;Major Recommendations&quot;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate medical and surgical management of patients with acute stroke&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Acute blood pressure therapy (i.e., within first 48 hours) remains controversial with both high and low blood pressure found to negatively affect patient outcomes. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Thrombolysis is associated with a risk of intracerebral haemorrhage (ICH) at the end of three or six month follow-up. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Recombinant Tissue Plasminogen Activator (rt-PA)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ABSOLUTE contraindications: Do NOT administer rt-PA if any of these statements are true.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Uncertainty about time of stroke onset (e.g., patients awaking from sleep). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Coma or severe obtundation with fixed eye deviation and complete hemiplegia. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Only minor stroke deficit which is rapidly improving. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Seizure observed or known to have occurred at onset of stroke. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertension: systolic blood pressure &amp;ge;185 mmHg or diastolic blood pressure &amp;gt;110 mmHg on repeated measures prior to study. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical presentation suggestive of subarachnoid haemorrhage even if the computed tomography (CT) scan is normal. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Presumed septic embolus. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient has received heparin with the last 48 hours and has elevated partial thromboplastin time (PTT) or has a known hereditary or acquired haemorrhagic diathesis (e.g., partial thromboplastin [PT] or activated partial thromboplastin time [APTT] greater than normal). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;International normalized ratio (INR) &amp;gt;1.5. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Platelet count &amp;lt;100,000/micro liters &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum glucose &amp;lt;2.8 mmol/l or &amp;gt;22.0 mmol/l &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;RELATIVE contraindications: If any of the following statements is true, use rt-PA with caution. In each situation the balance of the potential risks and benefits must be carefully considered.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Severe neurological impairment with National Institutes of Health (NIH) Stroke Scale score &amp;gt;22. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Age &amp;gt;80 years. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CT evidence of extensive middle cerebral artery (MCA) territory infarction (sulcal effacement or blurring of grey-white junction in greater than 1/3 of MCA territory). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stroke or serious head trauma within the past three months where the risks of bleeding are considered to outweigh the benefits of therapy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Major surgery within the last 14 days. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient has known history of intracranial haemorrhage, subarachnoid haemorrhage, known intracranial arteriovenous malformation or previously known intracranial neoplasm such that, in the opinion of the clinician, the increased risk of intracranial bleeding would outweigh the potential benefits of treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Suspected recent (within 30 days) myocardial infarction. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recent (within 30 days) biopsy of a parenchymal organ or surgery that, in the opinion of the responsible clinician, would increase the risk of unmanageable (e.g., uncontrolled by local pressure) bleeding. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recent (within 30 days) trauma with internal injuries or ulcerative wounds. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gastrointestinal or urinary tract haemorrhage within the last 30 days or any active or recent haemorrhage that, in the opinion of the responsible clinician, would increase the risk of unmanageable (e.g., by local pressure) bleeding. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Arterial puncture at non-compressible site within the last seven days. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Concomitant serious, advanced or terminal illness or any other condition that, in the opinion of the responsible clinician, would pose a risk to treatment. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This document is a general guide to appropriate practice, to be followed subject to the clinician's judgment and the patient's preference in each individual case. The guidelines are designed to provide information to assist decision-making and are based on the best evidence available at the time of development. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The guidelines should not be seen as an inflexible recipe for stroke care, sometimes rather disparagingly called 'cookbook medicine'; rather, they provide a general guide to appropriate practice to be followed subject to the clinician's judgment and the patient's preference. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Using the Guidelines&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The primary goal of these guidelines is to help healthcare workers improve the quality and effectiveness of the care they provide.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Guidelines differ from clinical or care pathways (also referred to as critical pathways, care paths, integrated care pathways, case management plans, clinical care pathways or care maps). Guidelines are an overview of the current best evidence translated into clinically relevant statements. Care pathways are based on best practice guidelines but provide a local link between the guidelines and their use.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In considering implementation of these guidelines at a local level, health professionals are encouraged to identify the barriers and facilitators to evidence-based care within their environment to determine the best strategy for local needs. Where change is required, initial and ongoing education is essential and is relevant to all recommendations in these guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Implementation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Reviewing the evidence and developing evidence-based recommendations for care are only the first steps to ensuring that evidence-based care is available. Following publication, the guidelines must be disseminated to all those involved in stroke care, who will then identify ways in which the guidelines may be taken up at a local level.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Strategies by which guidelines can be disseminated and implemented include:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Distribution of education materials, for example, guidelines will be emailed to stroke clinicians via existing stroke networks. Concise guidelines for the majority of disciplines including general practitioners, nurses and doctors are planned. A link to the guidelines will be available on the National Stroke Foundation (NSF) website and will be sent to all appropriate universities, colleges, associations, societies and other professional organisations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Educational meetings, for example, interdisciplinary conferences or internet-based web conferences. Resources will be developed to aid workshop facilitators identify barriers and solutions in the implementation phase. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Educational outreach visits. A peer support model using centres viewed as champions in aspects of acute stroke management may be used in collaboration with national audit results. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Key opinion leaders. Educational resources will utilise key opinion leaders. It is also planned to have local champions facilitate workshops in their local areas. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Audit and feedback. Data from the National Stroke Audits will be fundamental to the implementation of these guidelines. A copy of relevant indicators covering organisation of care and clinical care will be available from the NSF along with key audit reports (see Appendix 4 in the original guideline document). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reminders. Electronic reminders should be used once local teams have identified key areas of quality improvement activities and commenced planned strategies. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The NSF strongly recommends a systematic approach to identifying gaps in service delivery, understanding local barriers or enablers to reducing those gaps and developing a clear plan of action to improve stroke services. The NSF has developed a comprehensive quality improvement (QI) program (known as StrokeLink) offering outreach visits by NSF staff using interactive educational formats linked to audit and feedback and local consensus processes. Implementation issues also need to consider the barriers to delivering services to Aboriginal and Torres Strait Islander (ATSI) people and develop models of stroke care that address local cultural and geographical needs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Existing resources and networks (see Appendix 2 in the original guideline document) can also support implementation of these stroke guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Timeliness " /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Acute medical and surgical management. In: Clinical guidelines for stroke management 2010. Melbourne (Australia): National Stroke Foundation; 2010 Sep. p. 58-67.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2007 Oct (revised 2010 Sep)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="National Stroke Foundation (Australia) - Nonprofit Organization" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Australian Government Department of Health and Ageing&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Expert Working Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Group Members&lt;/em&gt;: Assoc Prof Louise Ada, Physiotherapist, University of Sydney; Dr Beata Bajorek, Pharmacist, University of Sydney and Royal North Shore Hospital; Prof Alan Barber, Neurologist, Auckland City Hospital; Dr Christopher Beer, Geriatrician/clinical pharmacologist, University of Western Australia, Royal Perth and Mercy Hospitals; Assoc Prof Julie Bernhardt (co-chair), Physiotherapist, National Stroke Research Institute; Dr Geoff Boddice, Clinical Neuropsychologist /Clinical Psychologist, University of Queensland and Ipswich Hospital; Ms Brenda Booth, Consumer, Working Aged Group with Stroke, NSW; Assoc Prof Sandy Brauer, Physiotherapist, University of Queensland; Ms Louise Corben, Occupational Therapist, Monash Medical Centre and Bruce Lefroy Centre (Murdoch Childrens Research Institute); Prof Maria Crotty, Rehabilitation Specialist, Repatriation General Hospital; Prof Tricia Desmond, Neuroradiologist, Royal Melbourne Hospital; Ms Cindy Dilworth, Speech Pathologist, Royal Brisbane Hospital; Dr Steven Faux, Rehabilitation Physician, St Vincent's Hospital, Sydney; Prof Jonathan Golledge, Vascular Surgeon, Townsville Hospital; Dr Louise Gustafsson, Occupational Therapist, University of Queensland; Dr Hugh Grantham, Medical Director, SA Ambulance Service; Dr Deborah Hersh, Speech Pathologist, Australian Aphasia Association; Ms Sue-Ellen Hogg, Speech Pathologist, Port Kembla Hospital; Mr Kelvin Hill, Manager, Guidelines Program, National Stroke Foundation; Ms Louise-Anne Jordan, Manager Clinical Service Delivery, Hunter Stroke Service; Assoc Prof Lynette Joubert, Social Worker, The University of Melbourne; Prof Justin Kenardy, Clinical Psychologist, University of Queensland; Dr Jonathan Knott, Emergency Physician, Royal Melbourne Hospital; Dr Erin Lalor, Chief Executive Officer, National Stroke Foundation; Dr Elaine Leung, General Practitioner, Adelaide; Prof Richard Lindley (co-chair), Geriatrician, University of Sydney; Ms Judy Martineau, Nutrition Consultant, Wesley Hospital; Prof Sandy Middleton, Director, Nursing Research Institute, St Vincent's &amp;amp; Mater Health Sydney, Australian Catholic University, Director, National Centre for Clinical Outcomes Research (NaCCOR), Nursing and Midwifery; Dr Ramu Nachiappan, General Practitioner, Broken Hill; Prof Mark Nelson, General Practitioner, University of Tasmania; Prof Lin Perry, Professor of Nursing Research and Practice Development, University of Technology, Prince of Wales Hospital and Sydney Eye Hospital; Ms Fiona Simpson, Dietitian and Senior Research Fellow, Royal North Shore Hospital; Ms Trish Spreadborough, Nurse Unit Manager, Rehabilitation, Redcliffe Hospital; Ms Leah Wright, Senior Project Officer, Guidelines Program, National Stroke Foundation&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All members of the Expert Working Group (EWG) completed and signed a declaration of potential conflicts of interest. Members also declared any potential conflicts at the beginning of each meeting throughout the development process. Most had no perceived conflicts. The reasons for potential conflicts primarily involved receiving money from non-commercial and commercial organisations specifically for undertaking clinical research. This was expected given the expertise of members in clinical research. Only a small number of members had received financial support from commercial companies for consultancy or lecturing. A policy of managing conflicts of interest was used during the process.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist"><FieldValue Value="Australian and New Zealand Society for Geriatric Medicine - Medical Specialty Society" /><FieldValue Value="Australian College for Emergency Medicine - Medical Specialty Society" /><FieldValue Value="Australian College of Rural and Remote Medicine - Professional Association" /><FieldValue Value="Australian Physiotherapy Association - Medical Specialty Society" /><FieldValue Value="beyondblue: the national depression initiative - Nonprofit Organization" /><FieldValue Value="Carers Australia - Professional Association" /><FieldValue Value="Continence Foundation of Australia - Professional Association" /><FieldValue Value="Council of Ambulance Authorities (Australia) - Professional Association" /><FieldValue Value="Dietitians Association of Australia - Professional Association" /><FieldValue Value="Internal Medicine Society of Australia and New Zealand - Medical Specialty Society" /><FieldValue Value="Occupational Therapy Australia - Professional Association" /><FieldValue Value="Pharmacy Guild of Australia - For Profit Organization" /><FieldValue Value="Royal Australian and New Zealand College of Psychiatrists - Professional Association" /><FieldValue Value="Royal Australian College of General Practitioners - Professional Association" /><FieldValue Value="Royal College of Nursing, Australia - Professional Association" /><FieldValue Value="Speech Pathology Australia - Medical Specialty Society" /><FieldValue Value="Stroke Society of Australasia - Disease Specific Society" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Acute medical and surgical management. In: National Stroke Foundation. Clinical guidelines for acute stroke management. Melbourne (Australia): National Stroke Foundation; 2007 Oct. p. 22-9.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.strokefoundation.com.au/clinical-guidelines&quot; title=&quot;NSF Australia Web site&quot;&gt;National Stroke Foundation (Australia) Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the National Stroke Foundation (Australia), Level 7, 461 Bourke Street, Melbourne Victoria 3000, Australia.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinical guidelines for stroke management 2010 recommendations. Melbourne (Australia): National Stroke Foundation; 2010. 30 p. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ten things to know about the clinical guidelines for stroke management 2010. Melbourne (Australia): National Stroke Foundation; 2010. 1 p. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.strokefoundation.com.au/clinical-guidelines&quot; title=&quot;NSF Web site&quot;&gt;National Stroke Foundation (Australia) Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Also, the following concise guidelines are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinical guidelines for stroke management: A quick guide for general practitioners. 2010. 8 p. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical guidelines for stroke management: A quick guide for occupational therapy. 2010. 10 p. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical guidelines for stroke management: A quick guide for dietetics. 2010. 5 p. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical guidelines for stroke management: A quick guide for physiotherapy. 2010. 8 p. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical guidelines for stroke management: A quick guide for psychology. 2010. 8 p. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical guidelines for stroke management: A quick guide for social work. 2010. 7 p. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.strokefoundation.com.au/concise&quot; title=&quot;NSF Australia Web site&quot;&gt;National Stroke Foundation (Australia) Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the National Stroke Foundation (Australia), Level 7, 461 Bourke Street, Melbourne Victoria 3000, Australia.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;All about stroke. Melbourne (Australia): National Stroke Foundation; 2010. 5 p. Available in Portable Document Format (PDF) in English, Vietnamese, Chinese, Arabic, Italian and Greek from the &lt;a href=&quot;http://www.strokefoundation.com.au/translated-resources&quot; title=&quot;NSA Australia Web site&quot;&gt;National Stroke Foundation (Australia) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the National Stroke Foundation (Australia), Level 7, 461 Bourke Street, Melbourne Victoria 3000, Australia.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on November 26, 2008. The information was verified by the guideline developer on December 4, 2008. This NGC summary was update by ECRI Institute on January 24, 2011. This summary was updated by ECRI Institute on June 27, 2011 following the U.S. Food and Drug Administration advisory on Zocor (simvastatin). This summary was updated by ECRI Institute on October 28, 2013 following the U.S. Food and Drug Administration advisory on Acetaminophen.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
